Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.44 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.41 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28262741 | 0.82 | PARP1 (0.48) | HDAC11BCAT2 | |
| SCHEMBL3034724 | 0.76 | HDAC6 (0.48) | HDAC6HDAC8HDAC1PDCD1CD274 | |
| SCHEMBL3028568 | 0.75 | HDAC6 (0.50) | HDAC6HDAC8HDAC1HDAC3PDCD1 | |
| SCHEMBL3628103 | 0.75 | KDM4E (0.46) | BCAT2 | |
| SCHEMBL3032639 | 0.75 | HDAC6 (0.44) | HDAC6HDAC8HDAC1HDAC3HDAC11 | |
| SCHEMBL3032162 | 0.74 | HDAC6 (0.50) | HDAC6HDAC8HDAC1HDAC3PDCD1 | |
| SCHEMBL3035678 | 0.74 | HDAC6 (0.45) | HDAC6HDAC8HDAC1HDAC3HDAC11 | |
| SCHEMBL5405953 | 0.73 | MKNK1 (0.42) | BCAT2 | |
| SCHEMBL3031945 | 0.73 | HDAC6 (0.48) | HDAC6HDAC8HDAC1PDCD1CD274 | |
| SCHEMBL3034133 | 0.73 | HDAC6 (0.49) | HDAC6HDAC8HDAC1HDAC3PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216796-A1 | N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | KATTAR SOLOMON | 2010-08-26 | — | — | US | claimed |
| US-20100216796-A1 | N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | KATTAR SOLOMON | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216796-A1 | N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | BRDT, AADAC, ACIN1 | HDAC6 31/4885HDAC8 7/4885HDAC1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.